Terms: = Endocrine gland cancer AND DAXX, BING2, 1616, ENSG00000206206, MGC126246, Q9UER7, MGC126245, DAQB-126H3_2, DAP6 AND Prognosis
9526 results:
1. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian cancer.
Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
[TBL] [Abstract] [Full Text] [Related]
2. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
Zhang Q; Zhong ZZ; Wu T; He YQ
BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer.
Ren J; Wu S; Su T; Ding J; Chen F; Li J; Wang Z; Han L; Wu Z
Cancer Med; 2024 May; 13(9):e7229. PubMed ID: 38698688
[TBL] [Abstract] [Full Text] [Related]
4. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
5. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.
Kim J; Hong SS; Kim SH; Hwang HK; Kang CM
World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431
[TBL] [Abstract] [Full Text] [Related]
6. Lateral lymph node metastasis in papillary thyroid cancer: Is there a difference between PTC and PTMC?
Ma W; Guo Y; Hua T; Li L; Lv T; Wang J
Medicine (Baltimore); 2024 Apr; 103(17):e37734. PubMed ID: 38669400
[TBL] [Abstract] [Full Text] [Related]
7. Cardiovascular mortality risk in patients with ovarian cancer: a population-based study.
Hu ZL; Yuan YX; Xia MY; Li Y; Yang Y; Wang SN; Meng XZ; Sun MY; Wang N
J Ovarian Res; 2024 Apr; 17(1):88. PubMed ID: 38664732
[TBL] [Abstract] [Full Text] [Related]
8. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
[TBL] [Abstract] [Full Text] [Related]
9. CircPHGDH downregulation decreases papillary thyroid cancer progression through miR-122-5p/PKM2 axis.
Shen J; Ma Z; Yang J; Qu T; Xia Y; Xu Y; Zhou M; Liu W
BMC Cancer; 2024 Apr; 24(1):511. PubMed ID: 38654205
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic value of combined psoas muscle mass and controlling nutritional status in patients with pancreatic ductal adenocarcinoma: a retrospective cohort study.
Kuwabara S; Takeuchi Y; Sato O; Mizota T; Ichinokawa M; Murakawa K; Aoki Y; Ishido K; Ono K; Hirano S
BMC Surg; 2024 Apr; 24(1):116. PubMed ID: 38643112
[TBL] [Abstract] [Full Text] [Related]
11. Genetic diagnosis of endocrine disorders in Cyprus through the Cyprus Institute of Neurology and Genetics: an ENDO-ERN Reference Center.
Neocleous V; Fanis P; Toumba M; Skordis N; Phylactou LA
Orphanet J Rare Dis; 2024 Apr; 19(1):167. PubMed ID: 38637882
[TBL] [Abstract] [Full Text] [Related]
12. Integration of single-cell RNA-seq and bulk RNA-seq data to construct and validate a cancer-associated fibroblast-related prognostic signature for patients with ovarian cancer.
Shen L; Li A; Cui J; Liu H; Zhang S
J Ovarian Res; 2024 Apr; 17(1):82. PubMed ID: 38627854
[TBL] [Abstract] [Full Text] [Related]
13. [Gonadoblastoma: Clinicopathological study and literature review of 3 cases].
Bao ML; Li X; Chen G; Li H; Chen W; Li HX
Zhonghua Nan Ke Xue; 2023 Jul; 29(7):634-638. PubMed ID: 38619412
[TBL] [Abstract] [Full Text] [Related]
14. A 15-Inflammation-Related Gene Signature Predicts the prognosis of Patients With Pancreatic Ductal Adenocarcinoma.
Sun X; Song H; Sun X; Liao C; Wang G; Xu Y; Li L; Han Y; Xu C; Wang W; Cai S; Liang H; Yu H
Cancer Invest; 2024 Mar; 42(3):226-242. PubMed ID: 38616304
[TBL] [Abstract] [Full Text] [Related]
15. Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in Pancreatic Ductal Carcinoma.
Fujiwara-Tani R; Sasaki T; Bhawal UK; Mori S; Ogata R; Sasaki R; Ikemoto A; Kishi S; Fujii K; Ohmori H; Sho M; Kuniyasu H
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612866
[TBL] [Abstract] [Full Text] [Related]
16. Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study.
Huang J; Wang J; Xv J; Wang J; Wang G; Zhao Y
Clin Exp Med; 2024 Apr; 24(1):76. PubMed ID: 38607456
[TBL] [Abstract] [Full Text] [Related]
17. ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
Huang Y; Chen D; Bai Y; Zhang Y; Zheng Z; Fu Q; Yi B; Jiang Y; Zhang Z; Zhu J
BMC Cancer; 2024 Apr; 24(1):452. PubMed ID: 38605349
[TBL] [Abstract] [Full Text] [Related]
18. IFNα-induced BST2
Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
[TBL] [Abstract] [Full Text] [Related]
19. Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient.
Bhaskari J; Bhagat R; Shilpa V; Premalata CS; Krishnamoorthy L
J Ovarian Res; 2024 Apr; 17(1):77. PubMed ID: 38594780
[TBL] [Abstract] [Full Text] [Related]
20. Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours.
Du Y; Xiao Y; Guo W; Yao J; Lan T; Li S; Wen H; Zhu W; He G; Zheng H; Chen H
Biomed Eng Online; 2024 Apr; 23(1):41. PubMed ID: 38594729
[TBL] [Abstract] [Full Text] [Related]
[Next]
